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Dear Editor-in-Chief,  
Dear Professor Gittinger Jr,  
May we kindly ask you to consider our enclosed manuscript “Iris lymphoma – a systematic concept for 
diagnosis and treatment“ - as appropriate for publication in “Survey of Ophthalmology”.  
In August 2018 you accept our outline focussing on iris lymphoma, an important and special entity that 
deserve specific attention indepently from as well as in addition to the well-described vitreoretinal 
lymphomas. Herein, we describe the current multidisciplinary concepts for diagnosis, staging and 
treatment in iris lymphoma.  
For further discussion please do not hesitate to contact me by phone (+49 221 478 4300), by fax (+49 
221 478 5094) or by email (ludwig.heindl@uk-koeln.de) at your convenience.  
With many thanks and best regards,  
Sincerely yours,  
 
 
Ludwig M. Heindl, MD 
Ass. Professor of Ophthalmology 
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John Gittinger, Jr, MD 
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Treatment.  I think this is an important topic and your outline covers it well.  A ached is a copy of the journal’s
informa#on for authors packet.  Please review the instruc#ons before submi7ng.
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Dear Professor Gittinger Jr,
May we kindly ask you to consider our enclosed outline - “Iris Lymphoma - Concepts for Diagnosis, Staging and
Treatment“ - as appropriate for a review submission to “Survey of Ophthalmology”.
The proposed review will focus on iris lymphoma, an important and special entity that deserve specific attention
indepently from as well as in addition to the well-described vitreoretinal lymphomas. Herein, we describe the
current multidisciplinary concepts for diagnosis, staging and treatment in iris lymphoma.
For further discussion please do not hesitate to contact me by phone (+49 221 478 4300), by fax (+49 221 478
5094) or by email (ludwig.heindl@uk-koeln.de) at your convenience.
With many thanks and best regards,
Sincerely yours,
Ludwig M. Heindl, MD       
Ass. Professor of Ophthalmology
Director, Ophthalmic Oncology and Ophthalmic Plastic and Reconstructive Surgery Service
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Iris lymphomas are rare malignant neoplasms arising either as primary tumors in the 
iris or as secondary tumors involving the iris. This review on iris lymphomas 
summarizes previously published data and puts forward recommendations for work-
up strategies of suspected iris lymphoma cases. Our objective is to provide a 
structured overview of the typical clinical symptoms and signs, the pathologic, 
ophthalmic as well as hematologic work-up for diagnosis, treatment, and follow-up of 
iris lymphomas. Further, this review offers a flowchart how to diagnose and treat these 
tumors. 
Symptoms and clinical signs of iris lymphoma may mimic a fulminant anterior uveitis. 
Careful evaluation of these signs by experienced uveitis or tumor specialists, together 
with the patient’s medical records, may lead to the suspicion of an iris lymphoma. 
State-of-the-art diagnostics includes either a biopsy or fine needle aspiration of the iris 
or anterior chamber, respectively, and its subsequent pathologic work-up. Adjunctive 
analyses, - e.g. immunohistochemistry, clonality analysis and possibly mutational 
testing -, aid the diagnosis. In the case of lymphoma diagnosis, hematological staging 
including magnetic resonance imaging, serological testing and bone marrow analyses 
are required to determine the extent of the disease and allow for decision-making in 
subsequent patient management. Discussions within a multidisciplinary tumor board 
(including the ophthalmologists as well as the hematologists) will lead to the 
appropriate selection of treatment(s), including local and/or systemic therapies. Based 
on a review of the literature and on the combined authors’ experience, this article 
provides recommendations as to how to schedule and perform the follow-up of iris 





































































Intraocular lymphoma is subdivided by anatomic localization.14 Lymphomatous 
involvement of the iris is an extremely rare condition, with very little being known about 
the demographics and epidemiology of this disease. It is defined as a lymphoma with 
predominant involvement of the iris, and can be either a primary or secondary 
manifestation, with most cases in the literature being a secondary manifestation of an 
underlying systemic Non-Hodgkin lymphoma (NHL; Figure 1).13,14 The diagnosis of 
‘primary iris lymphoma’ is reached if there is no evidence of an underlying systemic 
lymphoma at the time of ocular diagnosis and staging examinations. It is to be 
distinguished from a primary ciliary body lymphoma with predominant involvement of 
the ciliary body; a primary choroidal lymphoma arising predominantly within the 
choroid; and primary vitreo-retinal lymphoma, occurring mainly within the vitreous 
and/or retina (usually without any choroidal disease; Figure 1).14  
Most iris lymphomas are B-cell NHL, but T-cell lymphomas can also occur in the iris; 
no iridal Hodgkin lymphoma has been described to date.36,40 Nevertheless, iris 
lymphomas tend to be a high-grade lesions, and are associated with aggressive 
subtypes of systemic lymphoma and thereby a poor prognosis.36,40 This clinical 
outcome also may be due to diagnosis delay, which is quite common, varying between 
weeks and months. Typically, iris lymphoma patients present with inflammatory clinical 
signs, and are often misdiagnosed initially with an anterior uveitis. A definitive 
diagnosis is ultimately achieved by tissue sampling or aqueous cytology.  
The purpose of this review is to provide diagnostic and therapeutic recommendations 



































































2. Review of the iris lymphoma literature 
To date ~30 publications describing ~50 cases of iris lymphoma has been published 
in PubMed during the last 40 years (Table 1).1,2,5,8,9,18,19,24,25,27,28,32,36,37,40-42,44,45,52-
54,60,61,64,66-68  
Most are single case reports, but there are also a couple of small case series. As 
mentioned above, B-cell NHL was the most dominant lymphoma subgroup, followed 
by T-cell lymphoma, and plasma cell myeloma (also termed multiple myeloma). More 
than 70% of the cases of iridal lymphoma were unilateral.  
Apart from a dominant iris involvement, scattered lymphoma cells were also observed 
within the adjacent anterior chamber and ciliary body in some patients. In the latter 
cases, it is not clear from the descriptions provided whether these lymphomas were 
primarily arising in the iris or whether they secondarily infiltrated the iris stroma by 
contiguous spread. In our review of the literature, it was indeed difficult to discriminate 
between cases that were primarily arising in the iris, and those that may have arisen 
within the anterior choroid/ciliary body and then secondarily infiltrated the iris. 
Therefore, for the purposes of this review, ‘iris lymphoma’ was strictly defined as that 
with predominant disease in the iris, to distinguish it from a ciliary body lymphoma with 
the bulk of the disease within the ciliary body, from a choroidal lymphoma with 
predominant lymphoma in this location, and from a vitreo-retinal lymphoma, with the 
disease occurring mainly within the vitreous and/or retina. This definition correlates 
with that provided by the Tumor Node Metastatis system for uveal melanoma.4 
Consequently, iris lymphoma cases with combined and extensive ciliary body-, 
choroidal- or vitreo-retinal lymphoma were excluded from this review. Taking this 
anatomical definition into account, it would appear that ~25% of the cases reported in 
the literature are primary iris lymphoma, and the remainder of the cases are secondary 
iris NHL (Table 2).  
The age range of patients with iris lymphomas was between 1 - 89 years with a peak 
in late 50s and early 60s (Table 2). The predilection of male and female patients with 
primary or secondary lymphoma as the same. Depending on the extent and subtype 
of the disease, patients were treated with either external beam irradiation, local 
intraocular treatments (e.g., Rituximab), systemic therapy or enucleation. Table 1 



































































3. Lymphopoiesis - opportunities for lymphocyte mutation towards lymphoma  
Knowledge of lymphopoiesis is critical in the understanding of the pathological 
mechanisms behind lymphoma development. At any stage of the differentiation 
pathway of lymphocytes, genetic alterations may arise in them leading to uncontrolled 
proliferation of a particular clone, and ultimately the initiation of a lymphoma.26,34,48 
These may arise in specific niches within the body (nodal or extranodal), potentially 
remain localized or spread and become systemic.26,34,48 
In the healthy person, an intact immune function depends on the regular production of 
lymphocytes in the bone marrow and thymus. Pluripotent hematopoietic stem cells, 
also the precursor cells for erythrocytes and platelets, are regulated by different 
cytokines and chemokines (e.g., interleukin-1, -6, -7 or stem cell factor) and develop 
into lymphatic precursor cells.26,34,48 These cells further differentiate into T- or B-
lymphocyte stem cells. The T-lymphocyte stem cell migrate into the thymus and 
undergo a positive or negative selection.26,34,48 After this selection process, these cells 
differentiate into either CD4+ or CD8+ cells, and are released into the lymph and blood 
system. Well-defined subtypes of T-cells are known with differing functions in the 
immune system.26,34,48 
B-lymphocyte stem cells are located in the bone marrow and spleen, and generate 
pro-and pre-B-cells, which differentiate into ‘immature’ B-cells. They are released as 
immune naïve competent B-cells into the blood and ultimately the lymph system. 
During this maturation phase, a key step is the production of a B-cell-receptor (BCR). 
B-cells without a competent BCR or one with insufficient antigenicity undergo 
apoptosis.26,34,48 
The bone marrow and thymus are considered the primary lymphatic organs, as both 
are the locations where hematopoietic stem cells develop into B- or T-lymphocytes. In 
contrast, lymph nodes, spleen, tonsil or mucosa-associated lymphatic tissue (M.A.L.T.) 
are considered as secondary lymphatic organs, where the B- or T-lymphocytes 
undergo further activation and maturation in lymphatic follicles.26,34,48 
Immunocompetent naïve lymphocytes circulate in the blood or reside in the lymphatic 
follicles of the secondary lymphatic organs. In these lymphatic follicles, most cells are 
B-lymphocytes, but also T-lymphocytes as well as macrophages and other antigen 
presenting cells. Before antigen exposure, these lymphoid follicles are called “primary 



































































specific architecture. For example, B-lymphocytes, such as naïve B-lymphocytes and 
memory cells, are mostly found in the cortex of a follicle. In the capsule of the follicle, 
B-lymphocytes proliferate with support of T-lymphocytes after a contact with an 
extrinsic antigen, and then differentiate also into plasma cells, providing the humoral 
response. B-lymphocyte that are considered inadequate on antigen exposure undergo 
apoptosis in the ‘germinal center’ of the secondary follicle.26,34,48 Figure 2 displays the 
different steps of lymphopoiesis, and the proposed stages during which mutations can 




































































4. Clinical signs and symptoms of iridal lymphoma 
Clinical signs and symptoms of an iridal lymphoma may overlap with those of an 
anterior uveitis, including visual acuity reduction, intraocular pressure elevation and 
pain, haze of the cornea, cells and flare in the anterior chamber, pseudohypopyon and 
hyphema. Apart from these unspecific features, a whitish mass in the iris with or without 
neovascularization, differs from an anterior uveitis as well as the appearance of 
‘pseudo-hypopyon’ (Figure 3a).36,40 Further, cell clumps or aggregates on a lytic 
background are more likely to comprise lymphoma cells. Due to its rarity and the 
similarity of its signs and symptoms to anterior uveitis, the diagnosis of an iris 
lymphoma, and thereby the commencement of its treatment, might be delayed. 
In addition to the ophthalmic signs and symptoms, so-called ‘B-symptoms’ associated 
with lymphoproliferative disorders, including unclear fever above 38°C, night sweats, 
and unexpected weight loss (more than 10% in 6 months), may be apparent, and 
ultimately guide the differential diagnosis and subsequent investigation of these 




































































5. Differential diagnosis - benign reactive lymphoid hyperplasia of the iris and 
other differential diagnoses 
One of the main differential diagnoses of iris lymphoma is “Benign reactive lymphoid 
hyperplasia” (BRLH) of the iris, which has been defined as a condition characterized 
by a mass of benign polyclonal B and T-lymphocytes and plasma cells infiltrating the 
iris stroma.12,56 Iridal BRLH appears either as a circumscribed lesion or as a diffuse 
amelanotic thickening of the iris stroma (Figure 3b). It typically shows an indolent 
course and may even self-resolve. BRLH can occur in association with other systemic 
conditions, such as the Castleman’s syndrome.7 BRLH may have been misclassified 
in the past with small cell B-NHL, such as extranodal marginal zone B-cell NHL or small 
lymphocytic lymphoma/leukemia being overlooked.12,56,58 Malignant transformation of 
BRLH can occur, but it appears to be very uncommon.33,38 
Because of its benign nature, BRLH of the iris is by nature less aggressive and shows 
well-circumscribed uveal involvement, thus implying that a ‘watch-and-wait’ follow-up 
investigation may help to discriminate between BRLH and any malignant disease. 
Further differential diagnoses for iris lymphoma include amelanotic iris nevi, amelanotic 
iris melanoma (Figure 3c), as well as other rare neoplasms, such as iris hemangiomas, 
adenoma of the iris pigment epithelium, leiomyoma as well rhabdomyosarcoma, or 
metastatic carcinoma (Figure 3c).43,59  
In particular, differentiation between an amelanotic iris melanoma and iris lymphoma 
can be difficult, due to similar and overlapping clinical signs of these lesions. There are 
certain features, however, which strongly hint towards the diagnosis of melanoma. 
These include a more densely appearing tumor with corectopia, ectropium uveae, 
glaucoma, hyphema and extraocular extension as well as feeder vessels.57 
Nevertheless, in unclear cases, histological analysis of a tissue or fine needle 
aspitation biopsy may be necessary, as the diagnosis obviously has a major impact on 
treatment choice. 
Finally, an inflammatory condition in the anterior chamber (e.g., juvenile 
xanthogranuloma of the iris or Koeppe nodes of the iris in sarcoidosis) may mimic an 




































































6. Ophthalmic work-up and fine needle aspiration biopsy/iris biopsy 
The first step of the ophthalmic work-up of iris lymphoma is a comprehensive 
ophthalmic examination, including taking a detailed medical history; visual acuity 
testing, formal visual field testing; intraocular pressure measurement; and investigating 
the anterior chamber with a slit lamp, followed by a fundoscopy (if possible). Formal 
visual field testing is performed to assess possible posterior segment/optic nerve 
involvement or CNS disease. Standardized echography including A- and B-scans, 
ultrasound bio microscopy (UBM), anterior chamber optical coherence tomography 
(AC-OCT) help to discriminate from other differential diagnoses. Both UBM and AS-
OCT provide information with respect to status of the iris pigment as well as to the 
density of the mass. Further, UBM displays the ciliary body and allows for examination 
of ciliary body infiltration, which AS-OCT is not able to provide. 
Apart from the usual comprehensive description of the clinical signs, photographic 
documentation of the anterior chamber and the iris is mandatory, in order to follow any 
progression of anterior chamber inflammation and/or the tumor itself including during 
treatment. Additionally, quantification of anterior chamber inflammation by laser flare 
photometry or by the use of the Standardized Uveitis Nomenclature allows for the 
quantification of aqueous flare and cells.30 
If all signs and symptoms suggest a clinical diagnosis of lymphoma, biopsy is 
mandatory to confirm the diagnosis and to allow for its exact subtyping according to 
the WHO Lymphoma Classification, updated in 2016.47 This is key for the subsequent 
choice of treatment. 
To undertake an iris biopsy, two approaches are possible: to date, there is no evidence 
that one approach is better than the other. The first is an incisional surgical biopsy to 
obtain material from the suspicious iridal mass to get sufficient material for diagnostic 
purposes, without removal of the whole tumor.11,22,23,46 The second is an excisional 
resection of the tumor mass to obtain sufficient material for histopathological 
diagnostics but also with potential cure.62 Both approaches have their advantages and 
disadvantages. A small specimen procedure may be able to provide the diagnosis, and 
the residual tumor is then treated by either radiotherapy and/or chemotherapy. To date, 
there are no data indicating that a small sample biopsy might lead to a higher rate of 
recurrence, metastasis or earlier cancer-associated death. On the other hand, 
complete tumor excision is difficult in iris lymphoma, as these tumors are often not well-



































































inflammation in the anterior chamber and corneal clouding may make complete tumor 
excision impossible. In addition to incisional or excisional resections, a careful fine 
needle aspiration biopsy (FNAB) of the anterior chamber would be of value in cases 
where there is a reasonable scattering of lymphoma cells within the aqueous. Because 
of the small amount of material likely to be obtained, only a limited number of 
investigations would able to be performed on this FNAB; these would be determined 
by the morphology of the cells (see below). 
In some cases, unfortunately, the lymphomatous infiltration within the iris may be quite 
extensive involving the entire circumference of the iris, and also infiltrating into the 
chamber angle leading to secondary glaucoma and a painful eye. In such advanced 




































































7. Morphological, immunohistological and molecular biological diagnostics. 
Critical to the diagnosis of iris lymphoma is the morphological analysis of the biopsied 
cells. Following surgery, tissue biopsies and FNAB can be placed in a soft fixative, 
such as Cytolyt, and sent to the laboratory for further processing.16 Where tissue 
pieces are present, these would be embedded in paraffin and sectioned for 
conventional (e.g., hematoxylin and Eosin; H&E) and immunohistochemical staining. 
In contrast, the FNAB would be processed as cytospins, and stained with May 
Grunewald Giemsa (MGG), with spare cytospins being prepared for immunocytology. 
On the basis of the cytomorphology, the immunoprofile is selected, taking into account 
the limited amount of material and the main intent to subclassify the tumor as precisely 
as possible. The most common B-NHL involving the iris is a ‘diffuse large B-cell 
lymphoma’, whilst the small cell B-NHL can vary significantly according to the 
underlying systemic malignancy (e.g. chronic lymphocytic leukemia, mantle cell 
lymphoma).13,17 Should the lymphomatous lesion demonstrate a plasmacellular 
differentiation, a plasma cell myeloma must be excluded. Finally, in the case of 
immunosuppressed patients, an Epstein Barr virus-related lymphomatous lesion must 
be considered.8,50 Table 1 shows the available immune profile analyses in all case 
reports and series of iris lymphomas. 
 
By definition, an autonomic clonal proliferation of B- or T-lymphocytes is a lymphoma. 
Polymerase chain reaction of the immunoglobulin genes (IgH-PCR) and of the T-cell 
receptor (TCR-PCR) is of value in confirming the diagnosis of B- and T-cell lymphomas, 
respectively, of the iris. In addition, cytogenetic features of the iris lymphoma cells may 
enable the exact lymphoma subtyping.13 This is essential in determining whether this 
is a primary or secondary manifestation in the eye. Newer next generation sequencing 
techniques, enabling the detection of both copy number alterations and mutations 
within tumor cells on very small intraocular samples, have recently been introduced 




































































8. Subsequent clinical analyses  
8a. Hematologic work-up (MRI, blood analyses, bone marrow analysis; 
depending on patient’s lymphoma history) 
As above, based on the review of the literature, 75% of iris lymphoma patients have 
an underlying systemic NHL. Therefore, after diagnosing an iridal lymphoma, the 
patient should be referred to the hematological team for staging investigations, which 
entail radiological imaging, as well as serological- and bone marrow examinations.63 
Clinical outcome of iridal lymphomas is very much dependent on the lymphoma stage 
and subtype.13,15  
The gold standard for imaging the extent of systemic lymphomatous infiltration includes 
magnetic resonance imaging (MRI) and positron emission tomography (PET).49,65 An 
alternative to MRI for staging is computed tomography (CT), particularly in cases with 
contraindications for MRI (e.g., patients with heart pacemaker) and PET, or bone 
infiltration. 
As can be ascertained from the above, strong inter-disciplinary cooperation between 
clinical teams is required, i.e., between the ophthalmologists, pathologists, 
hematologists, radiologists, and radiotherapists. 
8b. Staging 
Apart from the molecular pathological classification, hematological staging of the 
lymphoma in each patient is of great significance, particularly with respect to patient 
management. Using the information from the hematological work-up, most 
hematologists use the Ann Arbor classification, which has been defined for Hodgkin-
lymphoma and for NHLs.51 The Ann Arbor “Lugano” classification for Non-Hodgkin-




































































9. Treatment concepts for iris lymphoma 
9a. General considerations 
As above, after the establishment of the diagnosis, cases of iris lymphoma must be 
presented and discussed in internal multidisciplinary tumor boards. There are no 
standardized protocols for the treatment of iris lymphoma, due to the rarity of this 
disease. However, a personalized approach to patient treatment would include 
consideration of not only the particular iris lymphoma but also of the general condition 
of the patient and their particular personal circumstances and preferences. All 
treatment decisions should be made together with the patient. 
Some treatment options are applicable for disease limited to the iris, whilst others must 
take into account systemic disease. For example, a secondary leukemic manifestation 
in the iris must include both localized and systemic therapy. 
Iris lymphoma case reports describe the diagnoses and respective treatments in these 
patients, and these are summarized in Table 1. General considerations and 
assumptions for treatment of iris lymphoma are evaluated and described below. Figure 
5 demonstrates a possible work-up for iris lymphoma including information, how to 
diagnose iris lymphoma and how to develop a treatment concept for these patients.  
9b. Systemic medical drug treatment 
Most iris lymphomas are treated by systemic chemotherapy, chemo-immune-therapy, 
checkpoint inhibitors, or further targeted therapies.20,35 A combination of the mentioned 
therapy is often required and are most likely established by an experienced 
hematologist. 
9c. External beam radiation 
In cases of primary lymphoma, external beam irradiation could also be a treatment 
option.39 This is also the case with secondary iris lymphomas with disturbing or sight-
threating ocular symptoms. The dose is dependant on lymphoma type, usage of 
additional systemic medication and the purpose of treatment (curative versus 
palliative), is usually between 40-80 Gray. Further, different options such as linear 
accelerator, proton beam radiation, gamma knife radiation or cyber knife radiation may 
also be used in this condition.6 
9d. Ocular medical drug treatment 
In some cases, iris lymphoma is treated locally with intraocular injections. To date, the 
most experience has been gained using intravitreal methotrexate and/or rituximab.35 



































































The latter offers the advantage of having a depot effect up to 4 weeks, with little risk of 
it being washed out as quickly via the trabecular meshwork. Similar to external beam 
irradiation, ocular injection of chemotherapeutic agents only makes sense in isolated 
primary iris lymphoma or to support systemic therapy.  
9e. Surgery 
Surgical treatment options are less likely to cure iris lymphoma, unless the area 
affected is well-contained. However, it may be undertaken should the patient have 
developed a secondary glaucoma as a result of the iridal lymphoma.6 
9f. Watch and Wait – palliative approach 
In some very rare cases, depending of the patient’s age and general condition, a 
‘watch-and-wait’ approach (i.e. without the administration of any treatment) might be 
considered appropriate after appropriate clinical diagnostics and deliberation. The 
benefit and the disadvantages of therapy options should be discussed within the 
internal tumor board and with the patient.  
9g. Online Tool to choose treatment  
An important online tool to care lymphoma and cancer in general has been established 
with the National Comprehensive Cancer Network (www.nccn.org). For many 
lymphoma types, guidelines and recommendations are provided on this website. Here, 
oncological ophthalmologists find valuable information regarding lymphoma, which 



































































10. Follow-Up and further care (recommendation for ophthalmic and 
hematologic follow-up, psycho-oncology) 
After treatment, all patients with iris lymphoma must be monitored frequently. An 
ophthalmic follow-up of every 6 weeks for the first 3 months, and then every 3 months 
for the first three years are recommended by the authors. In the event of sight-threating 
conditions or painful symptoms these intervals might be shortened. A follow-up visit in 
the ophthalmology department should include visual acuity testing, visual field testing, 
intraocular pressure measuring, and investigating the anterior chamber using a slit 
lamp, followed by fundoscopy, standardized echography, UBM, anterior chamber 
OCT, and laser flare photometry. Most important for the monitoring of the tumor is 
photographic documentation of the iris and of the anterior chamber, pre- and post-
treatment.  
In addition to the ophthalmic follow-up, a hematological follow-up must be undertaken 
by the hematology team. Intervals are to be defined by the hematologist and might 
vary between 3 and 6 months initially. 
In the case of tumor recurrence either within the eye or systemically, the patient’s case 
has to re-evaluated by the internal tumor board.  
Within the medical care, all lymphoma patients should be offered a psycho-oncological 
support with diagnosis and throughout the complete treatment and after-care process. 
This practice is in accordance with all major lymphoma guidelines (www.nccn.org, 





































































To date, there are no standardized protocols for the treatment of iris lymphoma. 
Conclusions, concepts and experience in the diagnostics and treatment of systemic, 
and other intraocular lymphomas allow us here to extrapolate and draw-up 
recommendations for the treatment of iris lymphoma patients. As in all cancers, the 
multidisciplinary tumor board is key for therapeutic decision-making in iris lymphoma 
patients. Due to the rarity of this tumor, randomized clinical trials are very unlikely; 





































































12.Method of literature search: 
A PubMed search was performed using the search word combination „iris lymphoma“, 
“anterior chamber lymphoma”, “iris leukemia”, “anterior chamber leukemia”, “iris 
multiple myeloma”, “anterior chamber multiple myeloma”, “iris plasma cell myeloma”, 
“anterior chamber myeloma”, “iris plasmacytoma”, and “anterior chamber 
plasmacytoma”. English language literature listed in PubMed has been have been 
screened and included, if iris lymphoma cases have been described or otherwise 
excluded. Literature in general on lymphoma have been included, only if they 
contributed significant information or recommendations on characteristics, diagnosis 
or treatment of iris lymphoma. Further, as menitoned above ‘iris lymphoma’ has been 
defined as lymphoma predominantly within the iris; ciliary body lymphoma as disease 
predominantly within the ciliary body; choroidal lymphoma as that predominantly 
located within the choroid; and vitreo-retinal lymphoma as that arising predominately 
within the vitreous and/or retina (usually without uveal involvement). Accordingly, iris 
lymphoma cases with combined ciliary body-, choroidal- or vitreo-retinal lymphoma 





































































AC-OCT anterior chamber optical coherence tomography 
BCR   B-cell-receptor  
BRLH  Benign reactive lymphoid hyperplasia  
CD  Cluster of differentiation 
CNS  Central nervous system 
CT   computer tomography 
MALT  Mucosa-associated lymphatic tissue 
MRI   magnetic resonance imaging 
NHL   Non-Hodgkin lymphoma 
PET   positron emission tomography 
UBM   Ultrasound bio microscopy  
WHO  World health organization 
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Fig. 1 Anatomical classification of intraocular lymphomas 
 
This figure shows the current understanding of intraocular lymphoma based primarily 
on the affected anatomic structure. Iris lymphoma has been defined as lymphoma 
predominantly affecting the iris; ciliary body lymphoma, as that affecting predominantly 
the ciliary body; choroidal lymphoma as that occurring predominantly  within the 
choroid; and vitreo-retinal lymphoma as that arising mainly within the vitreous and/or 
retina. This correlates with the TNM/AJCC definition of uveal melanomas (i.e. iris, 
ciliary body and choroidal melanomas).  
* Lymphomatous disease is predominant in the iris and iris root  
** Lymphomatous disease is dominant in ciliary body 
*** Lymphomatous disease is dominant in choroid  
(modified from 14). 
 
 
Fig. 2 Lymphopoiesis  
 
The figure shows the process of lymphopoiesis and therefore also potential stages for 
lymphoma development, as previously modified published.31,55 
 
 
Fig. 3 Iris tumors 
 
a) Iris lymphoma: The photograph shows a whitish mass and pseudohypopyon in 
the anterior chamber filling the whole chamber angle and touching the cornea 
at 6 o’clock. 
b) Benign reactive lymphoid hyperplasia of the iris: The photomicrograph shows 
an almost similar looking iris mass, less prominent in size. 
c) Iris melanoma: A typical brown mass within the iris in this photography is the 
key feature to discriminate between iris lymphoma and melanoma. 
d) Metastasis within the iris and in the anterior chamber of a bronchial carcinoma 
patient: Massive infiltration of the whole anterior chamber, including a 



































































Fig. 4 Histopathological photomicrograph  
 
Extensive secondary iris lymphoma: The histopathological photographs show a 
secondary manifestation of a diffuse large cell B-cell lymphoma in a 68-year old male 
(a) Hematoxylin-and-eosin (H&E) stain, showing the cornea (left) and the 
lymphomatous infiltration in the iris (right), with tumour cell ‘spillage’ into both the 
anterior and posterior chambers. The iris pigmented epithelium is detached from the 
iris stroma due to the large number of lymphoma cells. b) H&E stain of the iris 
lymphoma at higher magnification demonstrating the morphology of the large B-cells 
with numerous mitoses and occasional apoptotic bodies. c) PAX5 staining of the 
lymphoma cells; d) high magnification of the lymphoma cells seen in the anterior 
chamber within fibrin strands. The patient was initially treated with low-dose 
radiotherapy to the eye; however, unfortunately there was not a significant reduction 
in the lymphomatous infiltrate. Due to the secondary glaucoma and intractable pain, 
the eye was removed. 
 
 
Fig. 5 Work-up chart 
 









































































Tab. 1 Iris lymphoma case report overview 
 
The table summarizes clinical features of all case reports found following the described 
research rules in this manuscript. Case reports have been divided into a) all lymphoma 




Tab. 2 Summary of biodata for reviewed iris lymphoma cases 
 
The table summarizes the biodata of all predominate iris lymphoma case reports 
without plasma cell myeloma. Altogether, 43 cases have been analyzed for age range, 




Tab. 3 Lugano classification-modified Ann Arbor classification for Non-
Hodgkin Lymphoma 
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We are thankful that the Reviewers appear to be happy with all of our modifications to 
the text.  
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find an example of an advanced iris lymphoma, which has been added into the text as 
a replacement Figure 4 to the original one of the biopsy sample. Unfortunately, the 
slides of the iris biopsy still remain barred doors within the University of Liverpool and 
are likely to be inaccessible for another one month or two; however, we hope that he 
would find this case a suitable alternative.  
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Abstract 
Iris lymphomas are rare malignant neoplasms arising either as primary tumors in the 
iris or as secondary tumors involving the iris. We summarize previously published 
data and make recommendations for work-up strategies for cases of suspected iris 
lymphoma. Our objective is to provide a structured overview of the typical clinical 
symptoms and signs, the pathologic, ophthalmic as well as hematologic work-up for 
diagnosis, treatment, and follow-up of iris lymphomas and offer a flowchart on how to 




Intraocular lymphoma is subdivided by anatomic localization.14 Lymphomatous 
involvement of the iris is an extremely rare condition, with little being known about the 
demographics and epidemiology of this disease. It is defined as a lymphoma with 
predominant involvement of the iris and can be either a primary or secondary tumor, 
with most cases in the literature being a secondary manifestation of an underlying 
systemic non-Hodgkin lymphoma (NHL; Figure 1).13,14 The diagnosis of primary iris 
lymphoma is reached if there is no evidence of an underlying systemic lymphoma at 
the time of ocular diagnosis and staging examinations. This is to be distinguished 
from a primary ciliary body lymphoma with predominant involvement of the ciliary 
body, primary choroidal lymphoma arising predominantly within the choroid, and 
primary vitreo-retinal lymphoma occurring mainly within the vitreous and/or retina 
(usually without any choroidal disease--Figure 1).14  
Most iris lymphomas are B-cell NHL, but T-cell lymphomas may also occur in the iris. 
No iris Hodgkin lymphoma has been described to date.36,40 Nevertheless, iris 
lymphomas tend to be high-grade lesions, aggressive subtypes of systemic 
lymphoma with a poor prognosis.36,40 This clinical outcome also may be due to 
diagnosis delay, which is quite common, often weeks or months. Typically, iris 
lymphoma patients present with inflammatory clinical signs and are misdiagnosed 
initially as anterior uveitis. A definitive diagnosis is ultimately achieved by tissue 
sampling or aqueous cytology.  
We provide diagnostic and therapeutic recommendations, as well as a chart to guide 
work-up for patients with this disease. 
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2. Review of the iris lymphoma literature 
To date ~30 publications describing ~50 cases of iris lymphoma are indexed in 
PubMed over the last 40 years (Table 1).1,2,5,8,9,18,19,24,25,27,28,32,36,37,40-42,44,45,52-
54,60,61,64,66-68  
Most are single case reports, but there are also a couple of small case series. As 
mentioned above, B-cell NHL was the most dominant lymphoma subgroup, followed 
by T-cell lymphoma and plasma cell myeloma (also termed multiple myeloma). More 
than 70% of the cases of iris lymphoma were unilateral.  
Apart from a dominant iris involvement, scattered lymphoma cells were also 
observed within the adjacent anterior chamber and ciliary body in some patients. In 
the latter cases, it is not clear from the descriptions provided whether these 
lymphomas were primarily arising in the iris or whether they secondarily infiltrated the 
iris stroma by contiguous spread. In our review of the literature, it was indeed difficult 
to discriminate between cases that were primarily arising in the iris and those that 
may have arisen within the anterior choroid/ciliary body and then secondarily 
infiltrated the iris. Therefore, for the purposes of this review, iris lymphoma was 
strictly defined as that with predominant disease in the iris, to distinguish it from a 
ciliary body lymphoma with the bulk of the disease within the ciliary body, from a 
choroidal lymphoma with predominant lymphoma in this location, and from a vitreo-
retinal lymphoma, with the disease occurring mainly within the vitreous and/or retina. 
This definition correlates with that provided by the Tumor Node Metastatis system for 
uveal melanoma.4 Consequently, iris lymphoma cases with combined and extensive 
ciliary body-, choroidal- or vitreo-retinal lymphoma were excluded from this review. 
Taking this anatomical definition into account, it would appear that ~25% of the cases 
reported in the literature are primary iris lymphomas, and the remainder of the cases 
are secondary iris NHL (Table 2).  
The age range of patients with iris lymphomas was between 1 - 89 years, with a peak 
in the late 50s and early 60s (Table 2). The distribution of male and female patients 
with primary or secondary lymphoma is the same. Depending on the extent and 
subtype of the disease, patients were treated with external beam irradiation, local 
intraocular treatments (e.g., rituximab), systemic therapy, or enucleation. Table 1 
summarizes the data on all iris lymphoma cases found in our literature review. 
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3. Lymphopoiesis - opportunities for lymphocyte mutation towards lymphoma  
Knowledge of lymphopoiesis is critical in the understanding of the pathological 
mechanisms behind lymphoma development. At any stage of the differentiation 
pathway of lymphocytes, genetic alterations may arise leading to uncontrolled 
proliferation of a particular clone and ultimately the initiation of a lymphoma.26,34,48 
These may arise in specific niches within the body (nodal or extranodal), potentially 
remain localized, or spread and become systemic.26,34,48 
In the healthy person, an intact immune function depends on the regular production 
of lymphocytes in the bone marrow and thymus. Pluripotent hematopoietic stem 
cells, also the precursor cells for erythrocytes and platelets, are regulated by different 
cytokines and chemokines (e.g., interleukin-1, -6, -7 or stem cell factor) and develop 
into lymphatic precursor cells.26,34,48 These cells further differentiate into T- or B-
lymphocyte stem cells. The T-lymphocyte stem cell migrate into the thymus and 
undergo a positive or negative selection.26,34,48 After this selection process, these 
cells differentiate into either CD4+ or CD8+ cells and are released into the lymph and 
blood system. Well-defined subtypes of T-cells are known with differing functions in 
the immune system.26,34,48 
B-lymphocyte stem cells are located in the bone marrow and spleen and generate 
pro-and pre-B-cells, which differentiate into ‘immature’ B-cells. They are released as 
immune naïve B-cells into the blood and ultimately the lymphatic system. During this 
maturation phase, a key step is the production of a B-cell-receptor (BCR). B-cells 
without a competent BCR or one with insufficient antigenicity undergo 
apoptosis.26,34,48 
The bone marrow and thymus are considered the primary lymphatic organs, as both 
are the locations where hematopoietic stem cells develop into B- or T-lymphocytes. 
In contrast, lymph nodes, spleen, tonsil or mucosa-associated lymphatic tissue 
(M.A.L.T.) are considered as secondary lymphatic organs, where the B- or T-
lymphocytes undergo further activation and maturation in lymphatic follicles.26,34,48 
Immunocompetent naïve lymphocytes circulate in the blood or reside in the lymphatic 
follicles of the secondary lymphatic organs. In these lymphatic follicles, most cells are 
B-lymphocytes, but they also contain T-lymphocytes, as well as macrophages and 
other antigen presenting cells. Before antigen exposure, these lymphoid follicles are 
called “primary follicles”. After first antigen contact, they differentiate into “secondary 
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follicles” with a specific architecture. For example, B-lymphocytes, such as naïve B-
lymphocytes and memory cells, are mostly found in the cortex of a follicle. In the 
capsule of the follicle, B-lymphocytes proliferate with support of T-lymphocytes after 
a contact with an extrinsic antigen, and then differentiate also into plasma cells, 
providing the humoral response. B-lymphocyte that are considered inadequate on 
antigen exposure undergo apoptosis in the ‘germinal center’ of the secondary 
follicle.26,34,48 Figure 2 displays the different steps of lymphopoiesis and the proposed 




4. Clinical signs and symptoms of iris lymphoma 
Clinical signs and symptoms of an iris lymphoma may overlap with those of an 
anterior uveitis, including visual acuity reduction, intraocular pressure elevation and 
pain, haze of the cornea, cells and flare in the anterior chamber, pseudohypopyon, 
and hyphema. Apart from these nonspecific features, a whitish mass in the iris with 
or without neovascularization differs from an anterior uveitis as well as the 
appearance of ‘pseudohypopyon’ (Figure 3a).36,40 Further, cell clumps or aggregates 
on a lytic background are more likely to comprise lymphoma cells. Owing to its rarity 
and the similarity of its signs and symptoms to anterior uveitis, the diagnosis of an iris 
lymphoma, and thereby the commencement of its treatment, may be delayed. 
In addition to the ophthalmic signs and symptoms, so-called ‘B-symptoms’ 
associated with lymphoproliferative disorders, including fever above 38°C, night 
sweats, and unexpected weight loss (more than 10% in 6 months) may be apparent, 
and ultimately guide the differential diagnosis and subsequent investigation of these 
patients to its lymphomatous nature. 
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5. Differential diagnosis - benign reactive lymphoid hyperplasia of the iris and 
other differential diagnoses 
One of the main differential diagnoses of iris lymphoma is benign reactive lymphoid 
hyperplasia (BRLH) of the iris, which has been defined as a condition characterized 
by a mass of benign polyclonal B and T-lymphocytes and plasma cells infiltrating the 
iris stroma.12,56 Iris BRLH appears either as a circumscribed lesion or as a diffuse 
amelanotic thickening of the iris stroma (Figure 3b). It typically shows an indolent 
course and may even self-resolve. BRLH can occur in association with other 
systemic conditions, such as Castleman syndrome.7 BRLH may have been 
misclassified in the past with small cell B-NHL, such as extranodal marginal zone B-
cell NHL or small lymphocytic lymphoma/leukemia.12,56,58 Malignant transformation of 
BRLH can occur, but appears to be very uncommon.33,38 
Because of its benign nature, BRLH of the iris is by nature less aggressive and 
shows well-circumscribed uveal involvement, thus implying that a ‘watch-and-wait’ 
follow-up investigation may help to discriminate between BRLH and any malignant 
disease. 
Further differential diagnoses for iris lymphoma include amelanotic iris nevi, 
amelanotic iris melanoma (Figure 3c), as well as other rare neoplasms, such as iris 
hemangiomas, adenoma of the iris pigment epithelium, leiomyoma or 
rhabdomyosarcoma, or metastatic carcinoma (Figure 3c).43,59  
In particular, differentiation between an amelanotic iris melanoma and iris lymphoma 
can be difficult due to similar and overlapping clinical signs. There are certain 
features, however, that strongly suggest the diagnosis of melanoma. These include a 
more densely appearing tumor with corectopia, ectropium uveae, glaucoma, 
hyphema, extraocular extension, as well as feeder vessels.57 Nevertheless, in 
unclear cases, histological analysis of a tissue or fine needle aspiration biopsy may 
be necessary, as the diagnosis obviously has a major impact on treatment choice. 
Finally, an inflammatory condition in the anterior chamber (e.g., juvenile 
xanthogranuloma of the iris or Koeppe nodules of the iris in sarcoidosis) may mimic 




6. Ophthalmic work-up and fine needle aspiration biopsy/iris biopsy 
The first step of the ophthalmic work-up of iris lymphoma is a comprehensive 
ophthalmic examination, including taking a detailed medical history; visual acuity 
testing, formal visual field testing; intraocular pressure measurement; and 
investigating the anterior chamber with a slit lamp, followed by a funduscopy,if 
possible. Formal visual field testing is performed to assess possible posterior 
segment/optic nerve involvement or CNS disease. Standardized echography 
including A- and B-scans, ultrasound biomicroscopy (UBM), and anterior chamber 
optical coherence tomography (AC-OCT) help to narrow the differential. Both UBM 
and AS-OCT provide information with respect to status of the iris pigment as well as 
to the density of the mass. Further, UBM displays the ciliary body and allows for 
examination of ciliary body infiltration, which AS-OCT is not able to provide. 
Apart from the usual comprehensive description of the clinical signs, photographic 
documentation of the anterior chamber and the iris is mandatory, in order to follow 
any progression of anterior chamber inflammation and/or the tumor itself including 
during treatment. Additionally, quantification of anterior chamber inflammation by 
laser flare photometry or by the use of the Standardized Uveitis Nomenclature allows 
for the quantification of aqueous flare and cells.30 
If signs and symptoms suggest a clinical diagnosis of lymphoma, biopsy is 
mandatory to confirm the diagnosis and to allow for its exact subtyping according to 
the WHO Lymphoma Classification, updated in 2016.47 This is key for the 
subsequent choice of treatment. 
To undertake an iris biopsy, two approaches are possible To date, there is no 
evidence that one approach is better than the other. The first is an incisional surgical 
biopsy to obtain material from the suspicious iris mass sufficient for diagnostic 
purposes, without removal of the whole tumor.11,22,23,46 The second is an excisional 
resection of the tumor mass to obtain material for histopathological diagnosis, but 
also with the potential for cure.62 Both approaches have their advantages and 
disadvantages. A small specimen procedure may be able to provide the diagnosis, 
and the residual tumor is then treated by either radiotherapy and/or chemotherapy. 
There are no data indicating that a small sample biopsy might lead to a higher rate of 
recurrence, metastasis or earlier cancer-associated death. On the other hand, 
complete tumor excision is difficult in iris lymphoma, as these tumors are often not 
well-delineated and, thereby, difficult to remove completely from the eye. Further, 
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inflammation in the anterior chamber and corneal clouding may make complete 
tumor excision impossible. In addition to incisional or excisional resections, a careful 
fine needle aspiration biopsy (FNAB) of the anterior chamber would be of value in 
cases where there is a reasonable scattering of lymphoma cells within the aqueous. 
Because of the small amount of material likely to be obtained, only a limited number 
of investigations would able to be performed on this FNAB; these would be 
determined by the morphology of the cells (see below). 
In some cases, unfortunately, the lymphomatous infiltration within the iris may be 
involve the entire circumference of the iris, also infiltrating into the chamber angle 
leading to secondary glaucoma and a painful eye. In such advanced cases, 
enucleation may be the only option (Figure 4).  
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7. Morphological, immunohistological, and molecular biological diagnostics. 
Critical to the diagnosis of iris lymphoma is the morphological analysis of the biopsied 
cells. Following surgery, tissue biopsies and FNAB can be placed in a soft fixative, 
such as Cytolyt, and sent to the laboratory for further processing.16 Where tissue 
pieces are present, these would be embedded in paraffin and sectioned for 
conventional (e.g., hematoxylin and eosin; H&E) and immunohistochemical staining. 
In contrast, the FNAB would be processed as cytospins, and stained with May 
Grunewald Giemsa (MGG), with spare cytospins being prepared for immunocytology. 
On the basis of the cytomorphology, the immunoprofile is selected, taking into 
account the limited amount of material and the main intent to subclassify the tumor 
as precisely as possible. The most common B-NHL involving the iris is a ‘diffuse 
large B-cell lymphoma’, whilst the small cell B-NHL can vary significantly according to 
the underlying systemic malignancy (e.g. chronic lymphocytic leukemia, mantle cell 
lymphoma).13,17 Should the lymphomatous lesion demonstrate a plasmacellular 
differentiation, a plasma cell myeloma must be excluded. Finally, in the case of 
immunosuppressed patients, an Epstein Barr virus-related lymphomatous lesion 
must be considered.8,50 Table 1 shows the available immune profile analyses in all 
case reports and series of iris lymphomas. 
 
By definition, an autonomic clonal proliferation of B- or T-lymphocytes is a lymphoma. 
Polymerase chain reaction of the immunoglobulin genes (IgH-PCR) and of the T-cell 
receptor (TCR-PCR) is of value in confirming the diagnosis of B- and T-cell 
lymphomas, respectively, of the iris. In addition, cytogenetic features of the iris 
lymphoma cells may enable the exact lymphoma subtyping.13 This is essential in 
determining whether this is a primary or secondary manifestation in the eye. Newer 
next generation sequencing techniques, enabling the detection of both copy number 
alterations and mutations within tumor cells on small intraocular samples, have 
recently been introduced into the diagnostic repertoire.21 
  
 12 
8. Subsequent clinical analyses  
8a. Hematologic work-up (MRI, blood analyses, bone marrow analysis; 
depending on patient’s lymphoma history) 
As above, based on review of the literature, 75% of iris lymphoma patients have an 
underlying systemic NHL. Therefore, after diagnosing an iris lymphoma, the patient 
should be referred to a hematologist team for staging investigations, which entail 
radiological imaging, as well as serological and bone marrow examinations.63 Clinical 
outcome of iris lymphomas is very much dependent on the lymphoma stage and 
subtype.13,15  
The techniques for imaging the extent of systemic lymphomatous infiltration include 
magnetic resonance imaging (MRI) and positron emission tomography (PET).49,65 An 
alternative to MRI for staging is computed tomography, particularly in cases with 
contraindications for MRI (e.g., patients with pacemakers) or bone infiltration. 
As can be ascertained from the above, strong interdisciplinary cooperation between 
clinical teams is required, i.e., between the ophthalmologists, pathologists, 
hematologists, radiologists, and radiotherapists. 
8b. Staging 
Apart from the molecular pathological classification, hematological staging of the 
lymphoma in each patient is of great significance, particularly with respect to 
management. Using the information from the hematological work-up, most 
hematologists use the Ann Arbor classification, which has been defined for Hodgkin 
lymphoma and for NHL.51 The Ann Arbor “Lugano” classification for NHL is 
summarized in Table 3.10 
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9. Treatment concepts for iris lymphoma 
9a. General considerations 
As above, after the establishment of the diagnosis, cases of iris lymphoma must be 
presented and discussed in internal multidisciplinary tumor boards. There are no 
standardized protocols for the treatment of iris lymphoma, due to the rarity of this 
disease; however, a personalized approach to patient treatment would include 
consideration of not only the particular iris lymphoma, but also of the general 
condition of patients and their particular personal circumstances and preferences. All 
treatment decisions should be made together with the patient. 
Some treatment options are applicable for disease limited to the iris, while others 
must take into account systemic disease. For example, a secondary leukemic 
manifestation in the iris must include both localized and systemic therapy. 
Iris lymphoma case reports describe the diagnoses and respective treatments in 
these patients, and these are summarized in Table 1. General considerations and 
assumptions for treatment of iris lymphoma are evaluated and described below. 
Figure 5 demonstrates a possible work-up for iris lymphoma including information on 
how to diagnose iris lymphoma and how to develop a treatment concept for these 
patients.  
9b. Systemic medical drug treatment 
Most iris lymphomas are treated by systemic chemotherapy, chemo-immune-therapy, 
checkpoint inhibitors, or further targeted therapies.20,35 A combination of the 
mentioned therapy is often required and are most likely established by an 
experienced hematologist. 
9c. External beam radiation 
In cases of primary lymphoma, external beam irradiation could also be a treatment 
option.39 This is also the case with secondary iris lymphomas with disturbing or sight-
threating ocular symptoms. The dose is dependent on lymphoma type, usage of 
additional systemic medication, and the purpose of treatment (curative versus 
palliative), is usually between 40-80 Gray. Further, different options such as linear 
accelerator, proton beam radiation, gamma knife radiation, or cyber knife radiation 
may also be used in this condition.6 
9d. Ocular medical drug treatment 
In some cases, iris lymphoma is treated locally with intraocular injections. To date, 
the most experience has been gained using intravitreal methotrexate and/or 
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rituximab.35 These reagents are administered either into the anterior chamber or into 
the vitreous. The latter offers the advantage of having a depot effect up to 4 weeks, 
with little risk of it being washed out as quickly via the trabecular meshwork. Similar 
to external beam irradiation, ocular injection of chemotherapeutic agents only makes 
sense in isolated primary iris lymphoma or to support systemic therapy.  
9e. Surgery 
Surgical treatment options are less likely to cure iris lymphoma, unless the area 
affected is well-contained. However, it may be undertaken should the patient have 
developed a secondary glaucoma as a result of the iris lymphoma.6 
9f. Watch and wait – palliative approach 
In some rare cases, depending of the patient’s age and general condition, a ‘watch-
and-wait’ approach (i.e. without the administration of any treatment) might be 
considered appropriate after appropriate clinical diagnostics and deliberation. The 
benefit and the disadvantages of therapy options should be discussed within the 
internal tumor board and with the patient.  
9g. Online tool to choose treatment  
An important online tool to care lymphoma and cancer in general has been 
established with the National Comprehensive Cancer Network (www.nccn.org). For 
many lymphoma types, guidelines and recommendations are provided on this 
website. Here, oncological ophthalmologists find valuable information regarding 
lymphoma, which might be very helpful in secondary manifestation of these tumors in 
the iris.  
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10. Follow-Up and further care (recommendation for ophthalmic and 
hematologic follow-up, psycho-oncology) 
After treatment, all patients with iris lymphoma must be monitored frequently. An 
ophthalmic follow-up of every 6 weeks for the first 3 months, and then every 3 
months for the first three years are recommended. In the event of sight-threating 
conditions or painful symptoms, these intervals might be shortened. A follow-up visit 
in the ophthalmology department should include visual acuity and field testing,, 
intraocular pressure measurement, and visualizing the anterior chamber using a slit 
lamp, followed by funduscopy, standardized echography, UBM,  AC-OCT, and laser 
flare photometry. Most important for the monitoring of the tumor is photographic 
documentation of the iris and of the anterior chamber, pre- and post-treatment.  
In addition to the ophthalmic follow-up, follow-up must be undertaken by the 
hematology team. Intervals are to be defined by the hematologist and might vary 
between 3 and 6 months initially. 
In the case of tumor recurrence either within the eye or systemically, the case has to 
re-evaluated by the multidisciplinary tumor board.  
Within the medical care, all lymphoma patients should be offered a psycho-
oncological support with diagnosis and throughout the complete treatment and after-
care process. This practice is in accordance with all major lymphoma guidelines 




There is no current standardized protocol for the treatment of iris lymphoma. Our 
experience in the diagnostics and treatment of systemic and other intraocular 
lymphomas allows us to extrapolate from the data available and draw up 
recommendations for the treatment of iris lymphoma patients. As in all cancers, the 
multidisciplinary tumor board is essential for therapeutic decision-making in iris 
lymphoma patients. Owing to the rarity of this tumor, randomized clinical trials are 




12.Method of literature search: 
A PubMed search was performed using the search word combination „iris 
lymphoma“, “anterior chamber lymphoma”, “iris leukemia”, “anterior chamber 
leukemia”, “iris multiple myeloma”, “anterior chamber multiple myeloma”, “iris plasma 
cell myeloma”, “anterior chamber myeloma”, “iris plasmacytoma”, and “anterior 
chamber plasmacytoma”. English language literature listed in PubMed has been 
have been screened and included, if iris lymphoma cases have been described or 
otherwise excluded. Literature in general on lymphoma have been included, only if 
they contributed significant information or recommendations on characteristics, 
diagnosis or treatment of iris lymphoma. Further, as menitoned above ‘iris lymphoma’ 
has been defined as lymphoma predominantly within the iris; ciliary body lymphoma 
as disease predominantly within the ciliary body; choroidal lymphoma as that 
predominantly located within the choroid; and vitreo-retinal lymphoma as that arising 
predominately within the vitreous and/or retina (usually without uveal involvement). 
Accordingly, iris lymphoma cases with combined ciliary body-, choroidal- or vitreo-




AC-OCT anterior chamber optical coherence tomography 
BCR   B-cell-receptor  
BRLH  Benign reactive lymphoid hyperplasia  
CD  Cluster of differentiation 
CNS  Central nervous system 
CT   computer tomography 
MALT  Mucosa-associated lymphatic tissue 
MRI   magnetic resonance imaging 
NHL   Non-Hodgkin lymphoma 
PET   positron emission tomography 
UBM   Ultrasound bio microscopy  
WHO  World health organization 
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Fig. 1 Anatomical classification of intraocular lymphomas 
 
This figure shows the current understanding of intraocular lymphoma based primarily 
on the affected anatomic structure. Iris lymphoma has been defined as lymphoma 
predominantly affecting the iris; ciliary body lymphoma, as that affecting 
predominantly the ciliary body; choroidal lymphoma as that occurring predominantly  
within the choroid; and vitreo-retinal lymphoma as that arising mainly within the 
vitreous and/or retina. This correlates with the TNM/AJCC definition of uveal 
melanomas (i.e. iris, ciliary body and choroidal melanomas).  
* Lymphomatous disease is predominant in the iris and iris root  
** Lymphomatous disease is dominant in ciliary body 
*** Lymphomatous disease is dominant in choroid  
(modified from 14). 
 
 
Fig. 2 Lymphopoiesis  
 
The figure shows the process of lymphopoiesis and therefore also potential stages 
for lymphoma development, as previously modified published.31,55 
 
 
Fig. 3 Iris tumors 
 
a) Iris lymphoma: The photograph shows a whitish mass and pseudohypopyon in 
the anterior chamber filling the whole chamber angle and touching the cornea 
at 6 o’clock. 
b) Benign reactive lymphoid hyperplasia of the iris: The photomicrograph shows 
an almost similar looking iris mass, less prominent in size. 
c) Iris melanoma: A typical brown mass within the iris in this photography is the 
key feature to discriminate between iris lymphoma and melanoma. 
d) Metastasis within the iris and in the anterior chamber of a bronchial carcinoma 
patient: Massive infiltration of the whole anterior chamber, including a 
‘pseudohypopyon’ can be seen in this photomicrograph. 
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Fig. 4 Histopathological photomicrograph  
 
Extensive secondary iris lymphoma: The histopathological photographs show a 
secondary manifestation of a diffuse large cell B-cell lymphoma in a 68-year old male 
(a) Hematoxylin-and-eosin (H&E) stain, showing the cornea (left) and the 
lymphomatous infiltration in the iris (right), with tumour cell ‘spillage’ into both the 
anterior and posterior chambers. The iris pigmented epithelium is detached from the 
iris stroma due to the large number of lymphoma cells. b) H&E stain of the iris 
lymphoma at higher magnification demonstrating the morphology of the large B-cells 
with numerous mitoses and occasional apoptotic bodies. c) PAX5 staining of the 
lymphoma cells; d) high magnification of the lymphoma cells seen in the anterior 
chamber within fibrin strands. The patient was initially treated with low-dose 
radiotherapy to the eye; however, unfortunately there was not a significant reduction 
in the lymphomatous infiltrate. Due to the secondary glaucoma and intractable pain, 
the eye was removed. 
 
 
Fig. 5 Work-up chart 
 








Tab. 1 Iris lymphoma case report overview 
 
The table summarizes clinical features of all case reports found following the 
described research rules in this manuscript. Case reports have been divided into a) 
all lymphoma case reports without plasma cell myeloma; b) case series; and c) 
plasma cell myeloma case reports. 
 
 
Tab. 2 Summary of biodata for reviewed iris lymphoma cases 
 
The table summarizes the biodata of all predominate iris lymphoma case reports 
without plasma cell myeloma. Altogether, 43 cases have been analyzed for age 




Tab. 3 Lugano classification-modified Ann Arbor classification for Non-
Hodgkin Lymphoma 
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